DELCATH SYS INC (DCTH)
Health Care · Interventional oncology / liver-directed cancer therapy · NASDAQ
Interventional oncology company bringing a catheter-based chemotherapy delivery system to market for treating liver cancers, anchored by the newly FDA-approved HEPZATO kit for uveal melanoma metastases.
What DELCATH SYS INC does
Delcath Systems is an interventional oncology company focused on treating cancers primary or metastatic to the liver. The company's lead product, HEPZATO KIT (melphalan/hepatic delivery system), was FDA-approved in August 2023 for adult patients with uveal melanoma with unresectable hepatic metastases. HEPZATO combines a chemotherapy drug with a proprietary catheter-based delivery device to enable targeted treatment to the liver, with commercial launch beginning January 2024. The company also markets CHEMOSAT, its hepatic delivery system device (without drug), in Europe.
Themes: ["Interventional oncology","Liver cancer treatment","Orphan drugs / rare cancers","Uveal melanoma","Hepatocellular carcinoma","Metastatic liver cancer"]
Fundamentals
- Price$13.52 as of 2026-07-09 close
- Market cap$468M as of 2026-07-10
- 1-year return+8.9% as of 2026-07-09 close
- P/E833.50 as of 2026-07-10
- Net margin+0.6% as of 2026-07-10
- Gross margin+86.0% as of 2026-07-10
- ROE+0.5% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+68.0% as of 2026-07-10
- Revenue CAGR (3y)+215.3% SEC XBRL
- Beta0.52 as of 2026-07-10
Key risks (from latest filing)
["HEPZATO is a recently approved drug with limited commercial history and clinical adoption; commercial success depends on healthcare provider awareness, patient identification, and reimbursement","Company operates in narrow oncology indications with orphan drug designations; limited patient populations and market size concentration create revenue volatility risk","Medical device and combination product regulatory complexities; manufacturing and supply chain risks could disrupt commercialization, and company faces potential obsolescence or competitive pressure from alternative liver-directed therapies"]
Competitors & peers
- Varian Medical Systems (radiotherapy for hepatic tumors)
- Intuitive Surgical (minimally invasive surgical platforms)
- Boston Scientific (oncology and interventional devices)
- Exact Sciences (oncology diagnostics)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.